BPC-157 for pain: what the human evidence shows
Bottom line: BPC-157 has a substantial animal-research history and limited early human use, but completed human studies have not yet established how well it treats pain or speeds recovery. A 120-person Phase 2 hamstring trial is recruiting. No BPC-157 drug product or pain indication is FDA-approved, although an FDA advisory committee recommended adding BPC-157 to the 503A compounding list in July 2026.
What is actually known?
- FDA staff found five small human studies using BPC-157. Only one involved knee pain: a retrospective report with 17 people.
- The studies were small and short, so they cannot give a dependable estimate of benefit or long-term safety.
- A recruiting Phase 2 study plans to compare BPC-157 with placebo in 120 adults with MRI-confirmed hamstring injuries. Results have not been posted.
What the WADA ban tells us
The World Anti-Doping Agency explicitly names BPC-157 under category S0, “Non-Approved Substances.” It is prohibited for covered athletes at all times, both in and out of competition. BPC-157 was added as a named example in 2022 and remains on the 2026 Prohibited List.
That decision is meaningful: an international sports regulator considered BPC-157 relevant enough to control. It is an indirect signal rather than a clinical result. WADA can act on possible performance effects, health risk, and fairness in sport without waiting for a completed pain trial.
The useful interpretation: BPC-157 is a serious research subject, not something that should be dismissed as meaningless. At the same time, the size of any human benefit will remain uncertain until controlled trials report results.
Why interest grew before large human trials
Animal studies report effects involving blood vessels, inflammation, and tissue repair, and many patients and clinicians describe positive experiences. Those signals explain the interest and justify formal trials. They cannot yet tell us the average benefit, the best use, or which patients are most likely to respond.
Regulatory status
Two different FDA processes are easy to confuse. No BPC-157 drug product or indication has FDA approval. Separately, on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend BPC-157 free base and acetate for the 503A Bulks List. That recommendation could permit broader prescription compounding if FDA completes the required action, but an advisory vote is not approval of a drug.
FDA staff had recommended against adding BPC-157 to the compounding list, citing limited safety data and questions involving immune reactions, impurities, and product identification. The advisory committee reached a different recommendation after hearing the evidence and public testimony. Both parts of that record matter.
Primary sources
- FDA briefing document on BPC-157-related bulk drug substances (July 2026)
- FDA Pharmacy Compounding Advisory Committee meeting and materials (July 23–24, 2026)
- Associated Press report on the advisory committee vote (July 23, 2026)
- FDA list of bulk substances that may present significant safety risks
- ClinicalTrials.gov: BPC-157 for acute hamstring muscle strain repair
- WADA 2026 Prohibited List — BPC-157 is named under S0, prohibited at all times
- WADA committee minutes on the decision to name BPC-157 (2021)
Last reviewed: August 11, 2026.